Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab SC Extension in RA
NCT01772316Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2012
- Primary completion
- May 2015
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Started Dec 2012; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01772316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01772316.